Vident Advisory LLC Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Vident Advisory LLC raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,262 shares of the specialty pharmaceutical company’s stock after buying an additional 217 shares during the quarter. Vident Advisory LLC’s holdings in Jazz Pharmaceuticals were worth $3,604,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. LSV Asset Management lifted its position in Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock valued at $311,699,000 after buying an additional 37,108 shares during the period. Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Capital World Investors raised its position in shares of Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock worth $236,860,000 after purchasing an additional 104,195 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after purchasing an additional 315,608 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In other news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Seamus Mulligan acquired 100,000 shares of the stock in a transaction dated Friday, May 9th. The shares were bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 28,236 shares of company stock valued at $3,956,190 in the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 1.1%

Jazz Pharmaceuticals stock opened at $111.02 on Wednesday. The business has a 50-day simple moving average of $114.74 and a two-hundred day simple moving average of $122.01. The company has a market cap of $6.84 billion, a P/E ratio of 15.64, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.68 earnings per share. Analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on JAZZ shares. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. HC Wainwright lifted their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.